# A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

> **NCT05923099** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 262 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** LEO 138559
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05923099
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-20
- **Primary completion:** 2024-12-11
- **Final completion:** 2025-04-09
- **Target enrollment:** 262 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923099, "A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05923099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*